PRAX Articles, Praxis Precision Medicines Inc. - From 03/26/24

In the 45 mg cohort, 100% of patients achieved a complete response In the 15 mg cohort, 80% of patients achieved a complete response and 20% achi...

Presentation will be held virtually on Tuesday, March 26, 2024 at 8:00 a.m. ET Praxis leadership will be joined by key opinion leader in epilepsy ...

BOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translatin...

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is "too risky."...

Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guida...

BOSTON, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating...

BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translatin...

BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating...

BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating...